NCT02485535View on ClinicalTrials.gov

Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 4, 2015

Primary Completion Date

February 28, 2018

Study Completion Date

July 31, 2020

Conditions
Acute Myeloid Leukemiade Novo Myelodysplastic SyndromeMyelodysplastic SyndromeSecondary Acute Myeloid LeukemiaSecondary Myelodysplastic Syndrome
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Selinexor

Given PO

Trial Locations (1)

60637

University of Chicago Comprehensive Cancer Center, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Chicago

OTHER

NCT02485535 - Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant | Biotech Hunter | Biotech Hunter